| To: richardred who wrote (6000) | 10/27/2020 3:14:02 PM | | From: E_K_S | | | | You watch a company long enough, you understand management and if they are growing the company as they say and doing it from FCF and paying down debt vs other who just leverage their bets.
I like the former but hard to find a CEO w/ such history. Even on many of the deals you post, an investor must dig deeper to see their history and if it complements your own investment thesis.
I like growth but not at any price or by taking on too much debt. SJM (I own a few shares) is going to more growth. I own 10x more BGS because I like dividends and excess FCF that can be used to pay down debt and/or finance accretive acquisitions. Food stocks can be boring but for me, good hold as they grow the business organically and continue to generate all that FCF.
EKS |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: E_K_S | 10/27/2020 4:49:13 PM | | | | | | Why B&G Foods Is Buying the Crisco Brand and What It Might Mean for the Stock -- Barrons.com
Why B&G Foods Is Buying the Crisco Brand and What It Might Mean for the Stock -- Barrons.com
Dow Jones
By Teresa Rivas
B&G Foods said Tuesday it is buying the Crisco brand from J.M. Smucker, sending its shares higher in midday trading.
B&G (ticker: BGS) said it would acquire the oil and shortening business for $550 million in cash, in a deal that is slated to close next year.
The deal will bring Crisco into a portfolio that already includes some cooking and baking products. B&G may be best known for its frozen-food business -- its Green Giant vegetable brand accounted for nearly 22% of its sales in 2019 -- but it also owns Baker's Joy nonstick baking spray and Clabber Girl baking powder. Crisco is the leading brand of both shortening and vegetable oil, B&G noted in the news release.
Cooking and baking products have gotten a lift from the Covid-19 pandemic, with people spending more time at home and experimenting with new foods as they look to save money and eat healthier.
B&G stock was up 4.1% to $29.04, while J.M. Smucker (SJM) was off 0.9% to $114.05. The Dow Jones Industrial Average was down 0.4%.
Some analysts are upbeat about the deal. Piper Sandler's Michael Lavery, who has an Overweight rating on the shares, thinks the purchase "looks highly accretive...[as] Crisco can help build B&G's scale in baking products," and could lift the company's earnings per share by 50 cents to 55 cents in 2021.
RBC Capital Markets' Nik Modi has a Sector Perform rating on B&G but lifted his price target to $32 from $30, citing the acquisition. He views it as a positive, "leaning in to expectations at home food trends will remain elevated in a post-Covid world."
Credit Suisse's Robert Moskow, however, took a more-measured approach. He lifted his price target by $1, to $28, and wrote that Crisco is a good fit for B&G's portfolio. However, he reiterated a Neutral rating. He thinks consumers will continue to cook and bake more at home, even post-pandemic, but warned that Crisco was experiencing steady declines before Covid, "from consumers shifting to healthier oils and private label."
"Of the companies geared toward at-home food consumption, we prefer the ones with strong brand equity and a good track record for reinvesting behind them," he wrote, citing McCormick (MKC) and General Mills (GIS). |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: richardred who wrote (5984) | 10/28/2020 12:42:07 PM | | From: richardred | | | | ENZ-Speculation
Just a thought. miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc. This might give somewhat of an idea what ENZ Therapeutics unit is worth. Snip>The private placement is expected to result in gross proceeds to miRagen of approximately $91 million before deducting placement agent and other offering expenses. The proceeds from the private placement are intended to be used primarily to advance clinical studies of VRDN-001, a clinical-stage insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) in development for thyroid eye disease (TED), a debilitating condition that can cause bulging eyes, or proptosis, as well as double vision and potential blindness. ENZ has Optiquel T& others candidates in preclinical & beyond.
globenewswire.com/news-rele... |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: richardred who wrote (6004) | 10/28/2020 11:04:16 PM | | From: Robert O | | | | Marvell Nears Deal to Acquire Inphi for $10 Billion
Liana Baker and Ian King
Bloomberg•October 28, 2020
(Bloomberg) -- Marvell Technology Group Ltd. is nearing a deal to acquire Inphi Corp. for about $10 billion, according to a person familiar with the matter, adding to an already record year for chip industry deals.Marvell will pay 60% of the acquisition in stock, with the rest in cash, the person said. An announcement could come as soon as Thursday, said the person, who asked not to be identified as the information is private.
Dow Jones reported the acquisition earlier Wednesday. A representative for Inphi declined to comment, while a representative for Marvell didn’t immediately respond to a request for comment.Inphi is a maker of chips that act as the interface in gear that helps speed the flow of big chunks of information between computers and networks. Data center silicon is becoming increasing important as cloud providers are finding themselves swamped in data and look at even the most basic components to try to make their giant warehouses full of expensive equipment more efficient.
The purchase of Inphi adds to an already bumper year of announced transactions including Advanced Micro Devices Inc.’s $35 billion takeover of Xilinx Inc., Nividia Corp.’s $40-billion purchase of Arm Ltd. and Analog Devices Inc. agreement to acquire Maxim Integrated Products Inc. for $20.9 billion.Inphi counts Microsoft Corp. and Cisco Systems Inc. among its biggest customers, according to Bloomberg Supply Chain Analysis.Inphi stock has rallied 50% this year, even as it’s tried to overcome the loss of another large user of its chips, China’s Huawei Technologies Co. which has been cut off from U.S. suppliers by regulatory action. The company is on course to register an increase in revenue of almost 90% this year according to analysts’ estimates. |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: richardred | 10/30/2020 12:01:27 PM | | | | | | | Currently, given the most sizable liquid position I've ever been in my 35 years . Adding to ENZ today @ 1.85 |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: E_K_S who wrote (6008) | 11/2/2020 1:15:29 PM | | From: richardred | | | | | I don't own SFM SPROUTS FARMERS MARKET any more, but it seem overly punished for it latest reported earnings IMO. I think the analyst have read to much into slowing of growth moving forward. Once this pandemic is on it's way out. I still think SFM could be a potential low hanging fruit. (PUN INTENDED) |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (4) |
|
| |
